A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

AstraZeneca is backing up its considerable ... AZ’s investment comes as the company is seeing strong sales of HER2-targeted ADC Enhertu (trastuzumab deruxtecan) – which more than doubled ...

Da and Uncle Andy dissect the week’s news with sketches, jokes and the occasional song. The Best of Nolan Stephen talks to Stephen Travers, who survived a UVF attack on the Miami Showband ...